NeXstar afoul of promotion police
NeXstar Pharmaceuticals Inc.
has been forced to withdraw promotional materials for its
cancer drug following receipt of a nine-page warning letter from the FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC). The company (NXTR, Boulder, Colo.) declined to release the promotional materials or comment on the issues listed in the Feb. 21 warning letter. Spokesperson Joe Alper stated that the incident "is between the company and the FDA." The FDA, however, provided the letter to BioCentury. According to the letter, NXTR's promotional literature and other materials for DaunoXome (liposomal encapsulated daunorubicin) "contain statements, suggestions, or implications that are false and/or
Read the full 1309 word article